Dual-Antigen-Loaded Hepatitis B Virus Core Antigen Virus-like Particles Stimulate Efficient Immunotherapy Against Melanoma

2020 ◽  
Vol 12 (48) ◽  
pp. 53682-53690
Author(s):  
Keman Cheng ◽  
Tao Du ◽  
Yao Li ◽  
Yingqiu Qi ◽  
Huan Min ◽  
...  
Life ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 64
Author(s):  
Gergana Zahmanova ◽  
Milena Mazalovska ◽  
Katerina Takova ◽  
Valentina Toneva ◽  
Ivan Minkov ◽  
...  

The core antigen of hepatitis B virus (HBcAg) is capable of self-assembly into virus-like particles (VLPs) when expressed in a number of heterologous systems. Such VLPs are potential carriers of foreign antigenic sequences for vaccine design. In this study, we evaluated the production of chimeric HBcAg VLPs presenting a foreign epitope on their surface, the 551–607 amino acids (aa) immunological epitope of the ORF2 capsid protein of hepatitis E virus. A chimeric construct was made by the insertion of 56 aa into the immunodominant loop of the HBcAg. The sequences encoding the chimera were inserted into the pEAQ-HT vector and infiltrated into Nicotiana benthamiana leaves. The plant-expressed chimeric HBcHEV ORF2 551–607 protein was recognized by an anti-HBcAg mAb and anti-HEV IgG positive swine serum. Electron microscopy showed that plant-produced chimeric protein spontaneously assembled into “knobbly” ~34 nm diameter VLPs. This study shows that HBcAg is a promising carrier platform for the neutralizing epitopes of hepatitis E virus (HEV) and the chimeric HBcAg/HEV VLPs could be a candidate for a bivalent vaccine.


2013 ◽  
Vol 187 (1) ◽  
pp. 121-126 ◽  
Author(s):  
Razieh Monjezi ◽  
Sheau Wei Tan ◽  
Beng Ti Tey ◽  
Chin Chin Sieo ◽  
Wen Siang Tan

Virology ◽  
1981 ◽  
Vol 111 (2) ◽  
pp. 647-652 ◽  
Author(s):  
Prasanta R. Chakraborty ◽  
Nelson Ruiz-Opazo ◽  
David A. Shafritz

2004 ◽  
Vol 72 (11) ◽  
pp. 6519-6527 ◽  
Author(s):  
Elizabeth H. Nardin ◽  
Giane A. Oliveira ◽  
J. Mauricio Calvo-Calle ◽  
Kristiane Wetzel ◽  
Carolin Maier ◽  
...  

ABSTRACT We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escherichia coli, the recombinant ICC-1132 protein forms virus-like particles that were found to be highly immunogenic in preclinical studies of mice and monkeys. Twenty healthy adult volunteers received a 20- or a 50-μg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months. The majority of volunteers in the group receiving the 50-μg dose developed antibodies to CS repeats as well as to HBc. Malaria-specific T cells that secreted gamma interferon were also detected after a single immunization with ICC-1132-alum. These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens.


2010 ◽  
Vol 107 (20) ◽  
pp. 9340-9345 ◽  
Author(s):  
Y.-J. Lin ◽  
L.-R. Huang ◽  
H.-C. Yang ◽  
H.-T. Tzeng ◽  
P.-N. Hsu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document